Achondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies

16/10/2026

AI Summary

Achondroplasia results from a heterozygous FGFR3 p.Gly380Arg gain-of-function variant, causing hyperactive signalling that suppresses growth-plate chondrocyte proliferation and hypertrophic differentiation.
Mechanism-based therapies include NPR2/CNP axis agonists vosoritide and navepegritide, plus FGFR inhibitors like infigratinib; extracellular biologics remain investigational.
Gene-based strategies aim for FGFR3 expression tuning or variant-level genome editing but face delivery, dose control, redosing, immunogenicity and long-term safety challenges.

TL;DR (AI Generated)

In parallel, gene-based approaches are increasingly discussed as routes toward the etiology-directed control of the causal driver, ranging from the cartilage-biased tuning of FGFR3 expression to variant-level genome editing concepts.

Here, we synthesize the current therapeutic landscape, explicitly distinguish pathway-targeted disease modification from etiology-directed genetic strategies, and highlight the key translational barriers for gene-based approaches, including target-tissue delivery to the growth-plate, dose control and durability across development, redosing and immunogenicity constraints, and long-term safety.

Basic summary

Int J Mol Sci. 2026 Sep 25;27(19):8571. doi: 10.3390/ijms27198571.

ABSTRACT

Achondroplasia (ACH) is the most common non-lethal skeletal dysplasia and is caused in the vast majority of cases by a heterozygous gain-of-function variant in fibroblast growth factor receptor 3 (FGFR3, p.Gly380Arg). Hyperactive FGFR3 signaling constrains endochondral bone growth by suppressing growth-plate chondrocyte proliferation and hypertrophic differentiation. In the past decade, management has expanded beyond supportive care, and several mechanism-based interventions have shown disease-modifying effects in clinical studies. These include the activation of the NPR2/CNP axis with vosoritide and navepegritide and the pharmacologic attenuation of FGFR signaling with infigratinib, while extracellular biologics designed to modulate ligand-receptor interactions remain investigational. In parallel, gene-based approaches are increasingly discussed as routes toward the etiology-directed control of the causal driver, ranging from the cartilage-biased tuning of FGFR3 expression to variant-level genome editing concepts. Here, we synthesize the current therapeutic landscape, explicitly distinguish pathway-targeted disease modification from etiology-directed genetic strategies, and highlight the key translational barriers for gene-based approaches, including target-tissue delivery to the growth-plate, dose control and durability across development, redosing and immunogenicity constraints, and long-term safety.

PMID:42883818 | DOI:10.3390/ijms27198571

Document this CPD